Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Dermatology 2006; 212: 137-144.
- Keyword
-
-
Hautkrankheit
Dermatologie
- Event
-
Veröffentlichung
- (where)
-
Erlangen
- (who)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (when)
-
2013
- Contributor
- URN
-
urn:nbn:de:bvb:29-opus-43320
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sohn, Stefan
- Schöffski, Oliver
- Prinz, J.
- Reich, K.
- Schubert, E.
- Waldorf, K.
- Augustin, M.
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Time of origin
- 2013
Other Objects (12)
Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy
Cost-of-illness in psoriasis: Comparing inpatient and outpatient therapy
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Apremilast (Otezla) : mittelschwere Plaque-Psoriasis und moderate Psoriasis-Arthritis: optimale Versorgungsstrategien im Behandlungsalltag
Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Diabetes: cost of illness in Norway
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy
Cost-of-illness in psoriasis: Comparing inpatient and outpatient therapy
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Apremilast (Otezla) : mittelschwere Plaque-Psoriasis und moderate Psoriasis-Arthritis: optimale Versorgungsstrategien im Behandlungsalltag
Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Diabetes: cost of illness in Norway
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Plaque-Psoriasis – Ponesimod zeigt Wirksamkeit
Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy
Cost-of-illness in psoriasis: Comparing inpatient and outpatient therapy
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Apremilast (Otezla) : mittelschwere Plaque-Psoriasis und moderate Psoriasis-Arthritis: optimale Versorgungsstrategien im Behandlungsalltag
Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Diabetes: cost of illness in Norway
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis